Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Peripheral Blood Macrophages (PBMCs) from Adults with Sickle Cell Disease Have a Unique Phenotype

Christina Lisk, Francesca I Cendali, Delany Swindle, Gemlyn George, Kathryn Louise Hassell, Rachelle Nuss, Paul Buehler, Angelo D'Alessandro, David Irwin

Blood (2024) 144 (Supplement 1): 1143.

https://doi.org/10.1182/blood-2024-211244

Published: 2024

Journal Articles

Got Oxygen? the Impact of Band 3 on RBC Function during Exercise

Francesca I Cendali, Abby Grier, Christina Lisk, Monika Dzieciatkowska, Delany Swindle, Ariel M Hay, Travis Nemkov, David Irwin, James Zimring, Angelo D'Alessandro

Blood (2024) 144 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2024-210637

Published: 2024

Journal Articles

Low Dose Clodronate Improves Exercise Tolerance, Right Ventricular Function, and Alters Resident Lung Macrophage Phenotypes

Christina Lisk, Francesca I Cendali, Delany Swindle, Gemlyn George, Kathryn Louise Hassell, Rachelle Nuss, Angelo D'Alessandro, Paul Buehler, David Irwin

Blood (2024) 144 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2024-211429

Published: 2024

Journal Articles

Circulating Peripheral Blood Mononuclear Cells from Adults with Sickle Cell Disease (SCD)- Associated Pulmonary Hypertension (PH) Patients Have Increased Iron Content and a Unique Multi-Omic Signature

Christina Lisk, Francesca I Cendali, Delany Swindle, Gemlyn George, Rachelle Nuss, Kathryn Louise Hassell, Paul Buehler, Angelo D'Alessandro, David Irwin

Blood (2024) 144 (Supplement 1): 1116.

https://doi.org/10.1182/blood-2024-211406

Published: 2024

Journal Articles

Novel Humanized G6PD Deficient Mice Reveal Mechanisms of Increased Tolerance to Exercise As Gleaned By Multi-Omics in Models of Critical Speed

Francesca Cendali, Monika Dzieciatkowska, Christina Lisk, David Irwin, James C Zimring, Karolina Dziewulska-Cronk, Travis Nemkov, Angelo D'Alessandro

Blood (2023) 142 (Supplement 1): 2460.

https://doi.org/10.1182/blood-2023-179350

Published: 2023

Journal Articles

The Therapeutic Modalities of Sickle Cell Disease Reprogram the Platelet Functional-Bioenergetic Profile

Orlando Esparza, Giovanny Hernandez, Rachelle Nuss, David Irwin, Marguerite Kelher, Christopher C. Silliman, Kathryn L. Hassell, Pavel Davizon-Castillo

Blood (2021) 138 (Supplement 1): 957.

https://doi.org/10.1182/blood-2021-153908

Published: 2021

Journal Articles

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Blood (2011) 118 (21): 815.

https://doi.org/10.1182/blood.V118.21.815.815

Published: 2011

Journal Articles

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Pooja S. Raibagkar, MD, Paul G Richardson, Pieter Sonneveld, Michael W. Schuster, MD, David Irwin, MD, Edward A. Stadtmauer, MD, Thierry Facon, MD, Jean-Luc Harousseau, MD, Dina Ben-Yehuda, Sagar Lonial, MD, Hartmut Goldschmidt, Donna E. Reece, MD, Jesus F San Miguel, Joan Blade, Mario Boccadoro, Rachel Neuwirth, MS, Dixie-Lee Esseltine, MD, FRCPC, Kenneth C. Anderson, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 1963.

https://doi.org/10.1182/blood.V116.21.1963.1963

Published: 2010

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Bill Bensinger, MD, Robert Vescio, MD, Elber Camacho, MD, Jeffrey Wolf, MD, David Irwin, MD, Gerardo Capo, MD, Marti McKinley, MD, David H. Vesole, MD, Amitabha Mazumder, MD, John Crowley, MD, Dixie Esseltine, MD, Brian Durie, MD

Blood (2007) 110 (11): 188.

https://doi.org/10.1182/blood.V110.11.188.188

Published: 2007

Journal Articles

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Blood (2007) 110 (10): 3557–3560.

https://doi.org/10.1182/blood-2006-08-036947

Published: 2007

Includes: Supplemental data

Journal Articles

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Christine Chen, MD, Donna E. Reece, MD, David Siegel, MD, Ruben Niesvizky, MD, Ralph Vincent Boccia, MD, Edward A. Stadtmauer, MD, Rafat Abonour, MD, David Irwin, MD, Jonathan Polikoff, MD, Shaji Kumar, MD, Richard A. Gams, MD, Laurie Kenvin, RN,BS, Dale McElveen, MBA, Angela Hu, MS, Dennis Pietronigro, PhD, Robert D. Knight, MD, Jerome B. Zeldis, MD,PhD

Blood (2006) 108 (11): 3556.

https://doi.org/10.1182/blood.V108.11.3556.3556

Published: 2006

Journal Articles

Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.

Asher Alban Chanan-Khan, MD, Pieter Sonneveld, MD, Michael W. Schuster, MD, David Irwin, Edward A. Stadtmauer, MD, Thierry Facon, MD, Jean-Luc Harousseau, MD, Dina Ben-Yehuda, MD, Sagar Lonial, MD, Hartmut Goldschmidt, MD, Donna E. Reece, MD, Rachel B. Neuwirth, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2006) 108 (11): 3535.

https://doi.org/10.1182/blood.V108.11.3535.3535

Published: 2006

Journal Articles

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Brian G.M. Durie, MD, Jeffrey Lee Wolf, MD, Elber S. Camacho, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, BSN, Afshin Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, Robert Vescio, MD

Blood (2006) 108 (11): 796.

https://doi.org/10.1182/blood.V108.11.796.796

Published: 2006

Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1565.

https://doi.org/10.1182/blood.V106.11.1565.1565

Published: 2005

Journal Articles

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

Paul Gerard Guy Richardson, Bart Barlogie, James Berenson, Seema Singhal, Sundar Jagannath, David Irwin, S. Vincent Rajkumar, Teru Hideshima, Hugh Xiao, Dixie Esseltine, David Schenkein, Kenneth C. Anderson, for the SUMMIT Investigators

Blood (2005) 106 (9): 2977–2981.

https://doi.org/10.1182/blood-2005-02-0691

Published: 2005

Journal Articles

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.

Sundar Jagannath, MD, Durie Brian, MD, Jeffrey L. Wolf, MD, Elber Camacho, MD, David Irwin, MD, Jose Lutzky, MD, Marti McKinley, MD, Eli Gabayan, MD, Amitabha Mazumder, MD, John Crowley, PhD, David Schenkein, MD

Blood (2004) 104 (11): 333.

https://doi.org/10.1182/blood.V104.11.333.333

Published: 2004

Journal Articles

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Ann Mohrbacher, M.D., Shamel Sanani, M.D., David Irwin, M.D., Byron M. Espina, Catherine Madrid, Luigi Lenaz, M.D., Rosamerlinda Rosales

Blood (2004) 104 (11): 4592.

https://doi.org/10.1182/blood.V104.11.4592.4592

Published: 2004

NARROW

Peripheral Blood Macrophages (PBMCs) from Adults with Sickle Cell Disease Have a Unique Phenotype

Got Oxygen? the Impact of Band 3 on RBC Function during Exercise

Low Dose Clodronate Improves Exercise Tolerance, Right Ventricular Function, and Alters Resident Lung Macrophage Phenotypes

Circulating Peripheral Blood Mononuclear Cells from Adults with Sickle Cell Disease (SCD)- Associated Pulmonary Hypertension (PH) Patients Have Increased Iron Content and a Unique Multi-Omic Signature

Novel Humanized G6PD Deficient Mice Reveal Mechanisms of Increased Tolerance to Exercise As Gleaned By Multi-Omics in Models of Critical Speed

The Therapeutic Modalities of Sickle Cell Disease Reprogram the Platelet Functional-Bioenergetic Profile

Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study.

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma.

A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI-28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only